Question

Which of the following will not be a limitation for prodrug design?

(a) Formation of toxic product

(b) An inert carrier can be cleaved off forming toxic product

(c) Product cleaving off before reaching the target site

(d) The cleaving of the carrier is also site-specific

I had been asked this question during an interview for a job.

I'm obligated to ask this question of Prodrugs topic in chapter Prodrugs & Excretion of Drugs of Drug Biotechnology

Answer 1

Correct answer is (d) The cleaving of the carrier is also site-specific

To explain I would say: The limitation of the prodrug designing is the formation of unexpected metabolite, the inert carrier can be cleaved off forming a toxic molecule, and prodrug might consume vital nutrients. If the carrier cleavage is site specific it is an advantage.